Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 3/2013

01.05.2013 | Original Article

Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study

verfasst von: Anca Zimmermann, Paula Grigorescu-Sido, Heidi Rossmann, Karl J. Lackner, Cristina Drugan, Camelia Al Khzouz, Simona Bucerzan, Ioana Naşcu, Tim Zimmermann, Daniel Leucuţa, Matthias M. Weber

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Dyslipidemia in Gaucher disease includes reduced total, low-density lipoprotein (LDL)-, and high-density lipoprotein (HDL)-cholesterol (C). No prospective analysis of lipid profile changes in treatment-naïve patients under enzyme replacement therapy (ERT) is available.

Methods

We analyzed lipid profile changes during ERT in a prospective controlled manner. Twelve treatment-naïve patients, Gaucher disease type 1 (GD1), 29.5 ± 12.9 years, 4M/8F. Diagnosis was made by enzymatic measurement and mutational analysis. Total-, LDL-, and HDL-C, triglycerides (TG), and LDL subfractions were assessed before the start of ERT with imiglucerase and biannually for 3 years. Patients were matched with healthy controls before and after 3 years of ERT.

Results

At baseline, we found severely reduced HDL-C concentrations (23.6 ± 5.4 mg/dl) and enhanced LDL/HDL ratios (3.1 ± 0.7). HDL-C increased after 6 months (29.2 ± 5.7, p = 0.023), LDL/HDL ratio decreased after 30 months (2.5 ± 0.5, p = 0.039). TG, even not consistently enhanced at baseline (128 ± 31.3 mg/dl), yet higher than in controls (p < 0.001), decreased after 18 months, being comparable with controls after 3 years of ERT. Small, dense LDL (mg/dl) increased continuously without significant difference to controls. After 3 years of ERT, only reduced HDL-C concentrations persisted as a potentially atherogenic alteration; however, mean concentrations markedly improved (42.9 ± 8.3 mg/dl, p < 0.001). Lipid parameters correlated with six markers of disease severity.

Conclusions

This is the first prospective controlled study regarding lipid profile dynamics during ERT (glucocerebrosidase) in initially treatment-naïve GD1 patients. The most important changes were reduced HDL-C and enhanced LDL/HDL ratio. Their dynamics during ERT and correlations with markers of disease activity suggest that they can be considered markers of disease severity and follow-up in Gaucher patients under treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Alfonso PP, Cenarro A, Perez-Calvo JI, Puzo J, Giralt M, Giraldo P, Pocovi M (2003) Effect of enzyme replacement therapy on lipid profile in patients with Gaucher’s disease. Med Clin (Barc) 120(17):641–646 Alfonso PP, Cenarro A, Perez-Calvo JI, Puzo J, Giralt M, Giraldo P, Pocovi M (2003) Effect of enzyme replacement therapy on lipid profile in patients with Gaucher’s disease. Med Clin (Barc) 120(17):641–646
Zurück zum Zitat Andersson H, Kaplan P, Kacena K, Yec J (2008) Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 122:1182–1190PubMedCrossRef Andersson H, Kaplan P, Kacena K, Yec J (2008) Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 122:1182–1190PubMedCrossRef
Zurück zum Zitat Austin MA, King MC, Vranizan KM, Krauss RM (1990) Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82:495–506PubMedCrossRef Austin MA, King MC, Vranizan KM, Krauss RM (1990) Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82:495–506PubMedCrossRef
Zurück zum Zitat Barnevaeld RA, Keijzer W, Tegelaers FP, Ginns EI, Geurts van Kessel A, Brady RO et al (1983) Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q23 of chromosome 1 using monoclonal antibodies. Hum Genet 64:227–23CrossRef Barnevaeld RA, Keijzer W, Tegelaers FP, Ginns EI, Geurts van Kessel A, Brady RO et al (1983) Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q23 of chromosome 1 using monoclonal antibodies. Hum Genet 64:227–23CrossRef
Zurück zum Zitat Beutler E, Grabowski G (2001) Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Vaile D (eds) The metabolic and molecular bases of lnherited disease. Mc. Graw-Hill, New York, pp 3635–68 Beutler E, Grabowski G (2001) Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Vaile D (eds) The metabolic and molecular bases of lnherited disease. Mc. Graw-Hill, New York, pp 3635–68
Zurück zum Zitat Beutler E, Gelbart T, West C (1990) The facile detection of the nt 1226 mutation of glucocerebrosidase dose by mismatched PCR. Clin Chim Acta 194(2–3):161–166PubMedCrossRef Beutler E, Gelbart T, West C (1990) The facile detection of the nt 1226 mutation of glucocerebrosidase dose by mismatched PCR. Clin Chim Acta 194(2–3):161–166PubMedCrossRef
Zurück zum Zitat Beutler E, Gelbart T, Kuhl W, Sorhe J, West C (1991) Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state. Proc Natl Acad Sci USA 88:10544–547PubMedCrossRef Beutler E, Gelbart T, Kuhl W, Sorhe J, West C (1991) Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state. Proc Natl Acad Sci USA 88:10544–547PubMedCrossRef
Zurück zum Zitat Cenarro A, Pocovi M, Giraldo P, Garcia-Otin AL, Ordovas JM (1999) Plasma lipoprotein responses to enzyme-replacement in Gaucher’s disease. Lancet 353:642–643PubMedCrossRef Cenarro A, Pocovi M, Giraldo P, Garcia-Otin AL, Ordovas JM (1999) Plasma lipoprotein responses to enzyme-replacement in Gaucher’s disease. Lancet 353:642–643PubMedCrossRef
Zurück zum Zitat Chapman MJ, Goldstein S, Lagrange D, Laplaud PM (1981) A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 22:339–358PubMed Chapman MJ, Goldstein S, Lagrange D, Laplaud PM (1981) A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 22:339–358PubMed
Zurück zum Zitat Cohen II, Yaniv I, Baris H (2010) Diagnosis of severe type 1 Gaucher’s disease before irreversible damage occurs: is HDL cholesterol the answer? Brit J Haematol 150:108–127 Cohen II, Yaniv I, Baris H (2010) Diagnosis of severe type 1 Gaucher’s disease before irreversible damage occurs: is HDL cholesterol the answer? Brit J Haematol 150:108–127
Zurück zum Zitat Dahl N, Lagerström M, Erikson A, Pettersson U (1990) Simplified detection of Nci mutation in Gaucher disease. Lancet 335:1589–90PubMedCrossRef Dahl N, Lagerström M, Erikson A, Pettersson U (1990) Simplified detection of Nci mutation in Gaucher disease. Lancet 335:1589–90PubMedCrossRef
Zurück zum Zitat de Fost M, Langeveld M, Franssen R, Hutten BA, Groener JEM, de Groot E et al (2009) Low HDL cholesterol levels in type 1 Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis 204:267–272PubMedCrossRef de Fost M, Langeveld M, Franssen R, Hutten BA, Groener JEM, de Groot E et al (2009) Low HDL cholesterol levels in type 1 Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis 204:267–272PubMedCrossRef
Zurück zum Zitat Di Rocco M, Giona F, Carubbi F, Linari S, Minichilli F, Brady RO et al (2008) A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica 93(8):1211–18PubMedCrossRef Di Rocco M, Giona F, Carubbi F, Linari S, Minichilli F, Brady RO et al (2008) A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica 93(8):1211–18PubMedCrossRef
Zurück zum Zitat Drugan C, Procopciuc L, Jebeleanu G, Grigorescu-Sido P, Dussau J, Poenaru L et al (2002) Gaucher disease in Romanian patients: incidence of the most common mutations and phenotypic manifestations. Eur J Hum Genet 10:511–515PubMedCrossRef Drugan C, Procopciuc L, Jebeleanu G, Grigorescu-Sido P, Dussau J, Poenaru L et al (2002) Gaucher disease in Romanian patients: incidence of the most common mutations and phenotypic manifestations. Eur J Hum Genet 10:511–515PubMedCrossRef
Zurück zum Zitat Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC (2002) Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155(6):487–495PubMedCrossRef Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC (2002) Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155(6):487–495PubMedCrossRef
Zurück zum Zitat Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report on the National Cholesterol Education Program (NCEP) (1994) Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) Circ J Am Heart (formerly Circulation) 89:1333–1445 Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report on the National Cholesterol Education Program (NCEP) (1994) Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) Circ J Am Heart (formerly Circulation) 89:1333–1445
Zurück zum Zitat Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report on the National Cholesterol Education Program (NCEP) (2001) Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285:2486–2497 Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report on the National Cholesterol Education Program (NCEP) (2001) Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285:2486–2497
Zurück zum Zitat Geiss HC, Bremer S, Barrett PHR, Otto C, Parhofer KG (2004) In vivo metabolism of LDL subfractions in patients with homozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis. J Lipid Res 45:1459–67PubMedCrossRef Geiss HC, Bremer S, Barrett PHR, Otto C, Parhofer KG (2004) In vivo metabolism of LDL subfractions in patients with homozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis. J Lipid Res 45:1459–67PubMedCrossRef
Zurück zum Zitat Ginsberg H, Grabowski GA, Gibson JC, Fagerstrom R, Goldblatt J, Gilbert HS, Desnick RJ (1984) Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type 1 disease. Clin Genet 2:109–116 Ginsberg H, Grabowski GA, Gibson JC, Fagerstrom R, Goldblatt J, Gilbert HS, Desnick RJ (1984) Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type 1 disease. Clin Genet 2:109–116
Zurück zum Zitat Giraldo P, Pocovi M, Perez-Calvo JI, Rusio-Felix D, Giralt M (2000) On the behalf of Spanish Gaucher’s Disease Registry. Haematologica 85:792–799PubMed Giraldo P, Pocovi M, Perez-Calvo JI, Rusio-Felix D, Giralt M (2000) On the behalf of Spanish Gaucher’s Disease Registry. Haematologica 85:792–799PubMed
Zurück zum Zitat Grigorescu-Sido P, Drugan C, Al Khzouz C, Zimmermann A, Coldea C, Deneş C et al (2010) Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1. Eur J of Internal Med 21:104–113CrossRef Grigorescu-Sido P, Drugan C, Al Khzouz C, Zimmermann A, Coldea C, Deneş C et al (2010) Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1. Eur J of Internal Med 21:104–113CrossRef
Zurück zum Zitat Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lip Res 31(3):545–548 Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lip Res 31(3):545–548
Zurück zum Zitat Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93(3):1288–92PubMedCrossRef Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93(3):1288–92PubMedCrossRef
Zurück zum Zitat Lamarche B, Tchernof A, Moorjani S, Chantin B, Dagenais GR, Lupien PJ, Despres JP (1997) Small dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Circulation 95:69–75PubMedCrossRef Lamarche B, Tchernof A, Moorjani S, Chantin B, Dagenais GR, Lupien PJ, Despres JP (1997) Small dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Circulation 95:69–75PubMedCrossRef
Zurück zum Zitat Le NA, Gibson JC, Rubinstein A, Grabowski GA, Ginsberg HN (1988) Abnormalities in lipoprotein metabolism in Gaucher type 1 disease. Metabolism 37(3):240–245PubMedCrossRef Le NA, Gibson JC, Rubinstein A, Grabowski GA, Ginsberg HN (1988) Abnormalities in lipoprotein metabolism in Gaucher type 1 disease. Metabolism 37(3):240–245PubMedCrossRef
Zurück zum Zitat Lorberboym M, Vallabhajosula S, Lipszyc H, Pastores G (1997) Scintigraphic evaluation of Tc-99m-low-density lipoprotein (LDL) distribution in patients with Gaucher disease. Clin Genet 52(1):7–11PubMedCrossRef Lorberboym M, Vallabhajosula S, Lipszyc H, Pastores G (1997) Scintigraphic evaluation of Tc-99m-low-density lipoprotein (LDL) distribution in patients with Gaucher disease. Clin Genet 52(1):7–11PubMedCrossRef
Zurück zum Zitat Mehta A (2006) Epidemiology and natural history of Gaucher’s disease. Eur J Int Med 17(Suppl):S2–5CrossRef Mehta A (2006) Epidemiology and natural history of Gaucher’s disease. Eur J Int Med 17(Suppl):S2–5CrossRef
Zurück zum Zitat Meikle PJ, Fuller M, Hopwood JJ (2007) Epidemiology and screening policy. In: Futerman AM, Zimran A (eds) Gaucher disease. CRC Press, Taylor and Francis Group, FI, pp 321–340 Meikle PJ, Fuller M, Hopwood JJ (2007) Epidemiology and screening policy. In: Futerman AM, Zimran A (eds) Gaucher disease. CRC Press, Taylor and Francis Group, FI, pp 321–340
Zurück zum Zitat Nigon F, Lesnik P, Rouis M, Chapman MJ (1991) Discrete subspecies of human low density lipoproteins are heterogenous in their interaction with the cellular LDL receptor. J Lipid Res 32:1741–1753PubMed Nigon F, Lesnik P, Rouis M, Chapman MJ (1991) Discrete subspecies of human low density lipoproteins are heterogenous in their interaction with the cellular LDL receptor. J Lipid Res 32:1741–1753PubMed
Zurück zum Zitat Patlas M, Hadas-Halpern I, Abrahamov A, Zimran A, Elstein D (2002) Repeat abdominal ultrasound evaluation of 100 patients with type 1 Gaucher disease treated with enzyme replacement therapy for up to 7 years. Hematol J 3:17–20PubMedCrossRef Patlas M, Hadas-Halpern I, Abrahamov A, Zimran A, Elstein D (2002) Repeat abdominal ultrasound evaluation of 100 patients with type 1 Gaucher disease treated with enzyme replacement therapy for up to 7 years. Hematol J 3:17–20PubMedCrossRef
Zurück zum Zitat Peters SP, Coyle P, Glew RH (1976) Differenciation of beta-glucocerebrosidase from beta-glucosidase in human tissues using sodium taurocholate. Arch Biochem Biophys 175:569–582PubMedCrossRef Peters SP, Coyle P, Glew RH (1976) Differenciation of beta-glucocerebrosidase from beta-glucosidase in human tissues using sodium taurocholate. Arch Biochem Biophys 175:569–582PubMedCrossRef
Zurück zum Zitat Pocovi M, Cenarro A, Civeira F, Torralba MA, Perez-Calvo JI, Mozas P et al (1998) Beta-glucocerebrosidase gene locus as a link for Gaucher’s disease and familial hypo-alpha-lipoproteinemia. Lancet 351(9120):1919–1923PubMedCrossRef Pocovi M, Cenarro A, Civeira F, Torralba MA, Perez-Calvo JI, Mozas P et al (1998) Beta-glucocerebrosidase gene locus as a link for Gaucher’s disease and familial hypo-alpha-lipoproteinemia. Lancet 351(9120):1919–1923PubMedCrossRef
Zurück zum Zitat Puzo J, Alfonso P, Irun P, Gervas J, Pocovi M, Giraldo P (2010) Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy. Atherosclerosis 209(2):515–519PubMedCrossRef Puzo J, Alfonso P, Irun P, Gervas J, Pocovi M, Giraldo P (2010) Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy. Atherosclerosis 209(2):515–519PubMedCrossRef
Zurück zum Zitat Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S et al (2008) Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 73(5):430–440PubMedCrossRef Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S et al (2008) Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 73(5):430–440PubMedCrossRef
Zurück zum Zitat Stein P, Yang R, Liu J, Pastores GM, Mistry PK (2011) Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity. J Inherit Metab Dis 34:429–437PubMedCrossRef Stein P, Yang R, Liu J, Pastores GM, Mistry PK (2011) Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity. J Inherit Metab Dis 34:429–437PubMedCrossRef
Zurück zum Zitat Taddei TH (2010) High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. J Inherit Metab Dis 33(3):291–300PubMedCrossRef Taddei TH (2010) High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. J Inherit Metab Dis 33(3):291–300PubMedCrossRef
Zurück zum Zitat Tershakovek AM, Rader DJ (2004) Disorders of lipoprotein metabolism and transport. In: Behrman RE, Kliegman RM, Jenson HB (eds) Nelson textbook of pediatrics, 17th edn. Saunders, Philadelphia, p 448 Tershakovek AM, Rader DJ (2004) Disorders of lipoprotein metabolism and transport. In: Behrman RE, Kliegman RM, Jenson HB (eds) Nelson textbook of pediatrics, 17th edn. Saunders, Philadelphia, p 448
Zurück zum Zitat Vakkilainen J, Steiner G, Ansquer JC, Aaubin F, Rattier S, Foucher C et al (2003) Relationships between LDL lipoprotein particle size, plasma lipoproteins and progression of coronary artery disease. Circulation 107:1733–1737PubMedCrossRef Vakkilainen J, Steiner G, Ansquer JC, Aaubin F, Rattier S, Foucher C et al (2003) Relationships between LDL lipoprotein particle size, plasma lipoproteins and progression of coronary artery disease. Circulation 107:1733–1737PubMedCrossRef
Zurück zum Zitat von Eckardstein A, Nofer J, Assmann G (2001) High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21:13–27CrossRef von Eckardstein A, Nofer J, Assmann G (2001) High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21:13–27CrossRef
Zurück zum Zitat Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113:112–119PubMedCrossRef Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113:112–119PubMedCrossRef
Metadaten
Titel
Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study
verfasst von
Anca Zimmermann
Paula Grigorescu-Sido
Heidi Rossmann
Karl J. Lackner
Cristina Drugan
Camelia Al Khzouz
Simona Bucerzan
Ioana Naşcu
Tim Zimmermann
Daniel Leucuţa
Matthias M. Weber
Publikationsdatum
01.05.2013
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 3/2013
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-012-9529-3

Weitere Artikel der Ausgabe 3/2013

Journal of Inherited Metabolic Disease 3/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.